Nirvanol, also known as ethylphenylhydantoin, is a derivative of hydantoin with anticonvulsant properties. Its 5-ethyl-5-phenyl substitution pattern is similar to that of phenobarbital.[2] It is useful in the treatment of chorea.[3]
Clinical data | |
---|---|
Other names | 5-Ethyl-5-phenylhydantoin |
Routes of administration | By mouth[1] |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.010.138 |
Chemical and physical data | |
Formula | C11H12N2O2 |
Molar mass | 204.229 g·mol−1 |
3D model (JSmol) | |
| |
|
Metabolism
editMetabolism of nirvanol is stereoselective, with the (S)- enantiomer undergoing roughly 14 times more hydroxylation at the 4 position of the phenyl group than the (R)-enantiomer.[4][5]
References
edit- ^ Theodore WH, Newmark ME, Desai BT, Kupferberg HJ, Penry JK, Porter RJ, Yonekawa WD (August 1984). "Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients". Neurology. 34 (8): 1100–2. doi:10.1212/wnl.34.8.1100. PMID 6431315. S2CID 7925715.
- ^ Read WT (August 1922). "Researches on hydantoins. Synthesis of the soporific, 4,4-phenylethyl-hydantoin (nirvanol)". J. Am. Chem. Soc. 44 (8): 1746–55. doi:10.1021/ja01429a017.
- ^ Ashby HT (February 1930). "Treatment of Chorea by Nirvanol". Archives of Disease in Childhood. 5 (25): 42–3. doi:10.1136/adc.5.25.42. PMC 1975064. PMID 21031794.
- ^ Küpfer A, Patwardhan R, Ward S, Schenker S, Preisig R, Branch RA (July 1984). "Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans". The Journal of Pharmacology and Experimental Therapeutics. 230 (1): 28–33. PMID 6747829.
- ^ Butler TC (November 1953). "Quantitative studies of the physiological disposition of 3-methyl-5-ethyl-5-phenyl hydantoin (mesantoin) and 5-ethyl-5-phenyl hydantoin (nirvanol)". The Journal of Pharmacology and Experimental Therapeutics. 109 (3): 340–5. PMID 13109695.